Endo's financial results...as just reported (see below).
A company with a clear focus and strategy that does a pretty good job of growing revenue & earnings.
"The" company the holds the exclusive rights to develop and market Urocidin globally.
And, Endo has a need to see more branded pharmaceutical revenue (particularly when LIDODERM loses its patent protection in 2015 just as Urocidin is currently projected to hit the marketplace (by Taylor Collison)).
Just a matter of time. I have no problems waiting. Have a good one, rg
Endo Pharmaceuticals Reports Strong Fourth Quarter Financial Results; Provides 2012 Financial Guidance
- Total quarterly revenues of $803 million increase 57 percent versus prior year; branded pharmaceuticals revenues grow 16 percent, reflecting strong performance of OPANA® ER, Voltaren® Gel and LIDODERM®; Generics revenues grow 23 percent on a pro forma basis
- Reported quarterly diluted EPS of
.30 versus
.77 for prior year
- Adjusted diluted EPS of $1.40 reflecting growth of 32 percent from 2010
- Reported annual diluted EPS of $1.55, down 30 percent from prior year; adjusted diluted EPS of $4.69, reflecting growth of 35 percent from 2010
- Company issues 2012 guidance for revenue of $3.15 to $3.30 billion and adjusted diluted EPS of $5.00 to $5.20; expects reported or GAAP diluted EPS of $2.60 to $2.80
Press Release: Endo Pharmaceuticals –
Here's what the street expected:
Endo Pharmaceuticals Holdings Inc. is seen posting fourth-quarter earnings of $1.32 a share on sales of $803.4 million.
 |
Webcast
Q4 2011 Endo Pharmaceuticals Holdings Inc Earnings Conference Call (Live)
02/24/12 at 8:30 a.m. ET |
|
Webcast
ENDO PHARMACEUTICALS HLDGS INC at Citi Global Health Care Conference (Live)
02/27/12 at 9:30 a.m. ET |
|
Webcast
ENDO PHARMACEUTICALS HLDGS INC at Cowen Group Health Care Conference (Live)
03/07/12 at 10:40 a.m. ET |